# Tesamorelin FAQ: Common Questions, Answered from the Research > Tesamorelin FAQ: what it is, how it works, FDA approval, IGF-1, side effects, half-life, and fat-loss evidence — each answer cited to the published literature. Twenty-two of the most-asked questions about tesamorelin, each answered directly and cited where the answer makes a quantitative claim. ## What is tesamorelin? Tesamorelin is a synthetic, stabilized analogue of full-length human growth hormone-releasing hormone, GHRH(1-44), supplied clinically as the acetate salt [6]. Rather than supplying growth hormone, it stimulates the body's own pituitary to release it. It is a 44-amino-acid peptide, not a steroid, defined by an N-terminal trans-3-hexenoic acid group that resists enzymatic breakdown [6]. ## What does tesamorelin do? In the pivotal HIV trial, tesamorelin 2 mg/day reduced visceral abdominal fat by 15.2% (versus a 5.0% increase on placebo), lowered triglycerides by 50 mg/dL, and raised IGF-1 by 81.0% over 26 weeks [1]. It works by stimulating the body's own growth hormone, which drives IGF-1 and lipolysis preferentially in visceral fat [4]. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotrophs, raising cAMP and triggering pulsatile growth-hormone release; that growth hormone drives hepatic IGF-1 and lipolysis in visceral fat [4]. Because it amplifies the body's own pulsatile rhythm rather than supplying hormone from outside, its metabolic profile differs from recombinant growth hormone [7]. ## Is tesamorelin FDA approved? Yes, but only for one indication: it was approved in 2010 (NDA 022505) to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. Every other use — general fat loss, anti-aging, non-HIV fatty liver — is off-label and investigational. The approval scope is narrow and specific [5]. ## Is tesamorelin similar to GLP-1 weight-loss drugs? No. Tesamorelin is a GHRH analogue that stimulates endogenous growth hormone; it is a different molecular class from GLP-1 receptor agonists [6]. It was studied for visceral fat in HIV-associated lipodystrophy, not for general weight loss, and its mechanism — growth-hormone-driven lipolysis — is entirely distinct [1][4]. ## Is tesamorelin a peptide? Yes. It is a 44-amino-acid peptide, a stabilized analogue of GHRH(1-44) with a trans-3-hexenoic acid group on its N-terminus [6]. It is not a steroid and carries no steroid pharmacology — its only action is at the GHRH receptor on pituitary cells [4]. ## Will tesamorelin help me lose belly fat? In HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue selectively — by 15.2% over 26 weeks versus a 5.0% increase on placebo [1]. It is not approved or established for general belly-fat loss; the studied effect is on internal abdominal fat, not subcutaneous fat or overall BMI [4]. ## How long does it take to see fat loss from tesamorelin? Significant visceral-fat reduction was measured at 26 weeks in the pivotal RCTs [1] and sustained at roughly -18% over 52 weeks of continued dosing [2]. The benefit depended on continuing the drug — visceral fat reaccumulated within weeks of discontinuation [2]. ## Does tesamorelin burn belly fat? Trials measured a reduction in visceral adipose tissue driven by growth-hormone/IGF-1-mediated lipolysis [1]. The effect was on internal abdominal fat, not subcutaneous fat or overall BMI [4]. "Burning" is loose language; the literature describes selective visceral-fat lipolysis, measured by CT and MRI. ## Is tesamorelin a growth hormone? No. It does not supply growth hormone; it stimulates the pituitary to release the body's own [7]. In healthy men, tesamorelin raised mean overnight growth hormone (+0.5 ug/L, P=0.004) and IGF-1 (+181 ug/L, P<0.0001) without any exogenous growth hormone [4]. ## Does tesamorelin increase the risk of diabetes or affect blood sugar? In healthy men, insulin-stimulated glucose uptake was unchanged (P=0.61) and fasting glucose was unaffected (P=0.93) [4]; over 52 weeks, glucose changes were not clinically significant [2]. Monitoring is still warranted in people with prediabetes or dysglycemia, since growth-hormone stimulation can modestly perturb glucose. ## Does tesamorelin work for fat loss in non-HIV users? Pivotal efficacy trials were in HIV-positive adults [1][2]. Non-HIV human data are limited to a mechanistic study in healthy men [4]; no large general-population fat-loss RCT has been completed. Generalizability beyond HIV-associated lipodystrophy is mechanistically plausible but not established by trials [4]. ## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease? In a JAMA RCT of antiretroviral-treated HIV adults, tesamorelin reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) alongside a -42 cm2 visceral-fat treatment effect [3]. It remains investigational for non-alcoholic fatty liver disease (NAFLD/MASLD) and is not approved for it [5]. ## How does tesamorelin affect the liver in NAFLD? By reducing visceral fat and driving growth-hormone/IGF-1-mediated lipolysis, tesamorelin lowered hepatic lipid in HIV trials [3]. On safety, the NIH LiverTox monograph rates it likelihood score E — unlikely to cause clinically apparent liver injury, with no attributable cases and no de novo enzyme elevations reported in trials [5]. ## Can tesamorelin reduce liver fat? In the JAMA HIV trial it produced a net -2.9% reduction in hepatic lipid-to-water percentage (P=0.003) alongside a -42 cm2 visceral-fat treatment effect over six months [3]. The 2026 meta-analysis also reported a pooled hepatic-fat-fraction reduction of -4.28% across five RCTs [15]. ## What is the half-life of tesamorelin? Plasma exposure is short: population PK modeling reported apparent clearance of approximately 1,060 L/h [16], and secondary sources including the FDA label cite a terminal half-life of roughly 26-38 minutes [14]. Yet downstream IGF-1 stays elevated across the day, which is why once-daily dosing works [16]. ## How long does tesamorelin stay in your system? The peptide clears the plasma rapidly (apparent clearance ~1,060 L/h) [16], but its biological effect persists: trials reported sustained, dose-related IGF-1 elevation across the dosing interval [1][4]. So the molecule is short-lived while its downstream signal lasts the day, supporting once-daily administration [16]. ## What are the side effects of tesamorelin? The most common trial events were injection-site reactions and growth-hormone-class effects — arthralgia, headache, and peripheral oedema — with serious adverse events in fewer than 4% over 26 weeks [9]. The FDA label warns about stimulating growth hormone and raising serum IGF-1, and contraindicates active malignancy, hypersensitivity, and pregnancy [14]. ## Does tesamorelin cause water retention? Fluid-related effects, including peripheral oedema, are a recognized growth-hormone-class consideration carried in the prescribing label and seen across the trial program [9][14]. Over 52 weeks, the long-term safety program reported no new safety signals beyond growth-hormone-class effects [2]. ## Does tesamorelin increase the risk of cancer? Growth-hormone stimulation raises IGF-1, a growth factor — so the question is reasonable. Trials showed no excess malignancy signal over 52 weeks [2], but long-term oncologic-safety data are limited, and active malignancy is a labeled contraindication: treatment must be complete and the cancer inactive before use [14]. ## Who should not take tesamorelin / who should avoid it? The FDA label contraindicates it in active malignancy, in known hypersensitivity to tesamorelin or its excipients, and in pregnancy — animal organogenesis studies showed hydrocephaly in offspring [14]. It is also prohibited in sport under the WADA Prohibited List, category S2, as a GHRH analogue. ## Does tesamorelin raise IGF-1 levels? Yes. In the pivotal HIV trial, IGF-1 rose 81.0% over 26 weeks [1]; in healthy men it rose by 181 ug/L (P<0.0001) [4], reflecting growth-hormone-driven hepatic IGF-1 synthesis. The rise is dose-related — +48% at 1 mg and +65% at 2 mg in the dose-ranging study [8]. ## How does tesamorelin stimulate growth hormone release? It activates the Gs-coupled GHRH receptor on pituitary somatotrophs, raising cAMP and triggering pulsatile growth-hormone secretion [4]. In healthy men this raised mean overnight growth hormone by +0.5 ug/L (P=0.004) without supplying any growth hormone from outside [4]. The body makes the hormone; tesamorelin only presses the signal. --- The tesamorelin literature walked node by node — each trial figure, the GHRH-to-IGF-1 cascade, and the FDA-HIV-only scope chalked up where the studies put them and cited to source; a teaching board, not a clinic, a vendor, or a prescription.